{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T23:01:01Z","timestamp":1769554861874,"version":"3.49.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.numecd.2023.07.025","type":"journal-article","created":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T02:54:10Z","timestamp":1689994450000},"page":"2294-2305","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Treatment intensification following glucagon-like peptide-1 receptor agonist treatment in type 2 diabetes: The RESTORE-G real-world study"],"prefix":"10.1016","volume":"33","author":[{"given":"Riccardo","family":"Candido","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5939-6850","authenticated-orcid":false,"given":"Antonio","family":"Nicolucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Larosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8696-4238","authenticated-orcid":false,"given":"Maria Chiara","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaele","family":"Napoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Gabellieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Tortato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa Anna","family":"Rabini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalia","family":"Crazzolara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Lucibelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Concetta","family":"Aragiusto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluigi","family":"Panzolato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Di Mauro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Del Buono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Placentino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graziano","family":"Di Cianni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Brandoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Fazion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna","family":"Gregori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonino","family":"Di Benedetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"De Riva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annamaria","family":"Terracciano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaele","family":"Napoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciano","family":"Zenari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Placentino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco","family":"Cavalot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Porcellati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Anichini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Citro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"D'Angelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcello","family":"Arca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lelio","family":"Morviducci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa Anna","family":"Rabini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Montani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Lucibelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Placentino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Fiorentini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.numecd.2023.07.025_bib1","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3082","article-title":"GLP-1 receptor agonist added to insulin versus basal-plus or basal-bolus insulin therapy in type 2 diabetes: a systematic review and meta-analysis","volume":"35","author":"Castellana","year":"2019","journal-title":"Diabetes Metab Res Rev"},{"issue":"Suppl 1","key":"10.1016\/j.numecd.2023.07.025_bib2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/dom.13162","article-title":"A review of GLP-1 receptor agonists: evolution and advancement, through the lens of randomised controlled trials","volume":"20","author":"Aroda","year":"2018","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.numecd.2023.07.025_bib3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cmet.2016.06.009","article-title":"The cardiovascular biology of glucagon-like peptide-1","volume":"24","author":"Drucker","year":"2016","journal-title":"Cell Metabol"},{"key":"10.1016\/j.numecd.2023.07.025_bib4","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1203858","article-title":"Basal insulin and cardiovascular and other outcomes in dysglycemia","volume":"367","author":"Gerstein","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2023.07.025_bib5","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.diabet.2018.02.002","article-title":"Clinical perspectives from the BEGIN and EDITION programmes: trial-level meta-analyses outcomes with either degludec or glargine 300U\/mL vs glargine 100U\/mL in T2D","volume":"44","author":"Roussel","year":"2018","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.numecd.2023.07.025_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2018.11.004","article-title":"Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U\/mL) and insulin glargine (100, 300 U\/mL) - a review of evidence and clinical interpretation","volume":"45","author":"Owens","year":"2019","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.numecd.2023.07.025_bib7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.7326\/0003-4819-154-2-201101180-00300","article-title":"Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial","volume":"154","author":"Buse","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.numecd.2023.07.025_bib8","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.2337\/dc12-2454","article-title":"Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L)","volume":"36","author":"Riddle","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2023.07.025_bib9","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.2337\/dc12-2462","article-title":"Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1)","volume":"36","author":"Riddle","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2023.07.025_bib10","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.2337\/dc14-0001","article-title":"Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro","volume":"37","author":"Rosenstock","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2023.07.025_bib11","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/dom.12025","article-title":"Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature","volume":"15","author":"Balena","year":"2013","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.numecd.2023.07.025_bib12","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2174\/187221412800604563","article-title":"The novel use of GLP-1 analogue and insulin combination in type 2 diabetes mellitus","volume":"6","author":"Baruah","year":"2012","journal-title":"Recent Pat Endocr Metab Immune Drug Discov"},{"key":"10.1016\/j.numecd.2023.07.025_bib13","doi-asserted-by":"crossref","DOI":"10.2337\/cd17-0065","article-title":"Insulin\/glucagon-like peptide-1 receptor agonist combination therapy for the treatment of type 2 diabetes: are two agents better than one?","volume":"36","author":"Aroda","year":"2018","journal-title":"Clin Diabetes"},{"key":"10.1016\/j.numecd.2023.07.025_bib14","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1080\/03007995.2018.1541790","article-title":"Rationale for a titratable fixed-ratio co-formulation of a basal insulin analog and a glucagon-like peptide 1 receptor agonist in patients with type 2 diabetes","volume":"35","author":"Blonde","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.numecd.2023.07.025_bib15","doi-asserted-by":"crossref","first-page":"809","DOI":"10.2337\/dc17-er06d","article-title":"Efficacy and safety of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin: the LixiLan-L randomized trial","volume":"40","author":"Aroda","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2023.07.025_bib16","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.2337\/dc16-0917","article-title":"Benefits of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide, versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents: the LixiLan-O randomized trial","volume":"39","author":"Rosenstock","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2023.07.025_bib17","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.2337\/dc19-1357","article-title":"Switching to iGlarLixi versus continuing daily or weekly GLP-1 RA in type 2 diabetes inadequately controlled by GLP-1 RA and oral antihyperglycemic therapy: the LixiLan-G randomized clinical trial","volume":"42","author":"Blonde","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2023.07.025_bib18","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S2213-8587(14)70174-3","volume":"2","author":"Gough","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.numecd.2023.07.025_bib19","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s13300-016-0218-3","article-title":"The efficacy of IDegLira (insulin degludec\/liraglutide combination) in adults with type 2 diabetes inadequately controlled with a GLP-1 receptor agonist and oral therapy: DUAL III randomized clinical trial","volume":"8","author":"Linjawi","year":"2017","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.numecd.2023.07.025_bib20","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.2337\/dc14-0785","article-title":"Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira)","volume":"37","author":"Buse","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2023.07.025_bib21","doi-asserted-by":"crossref","DOI":"10.2337\/cd17-0064","volume":"36","author":"Wysham","year":"2018","journal-title":"Clin Diabetes"},{"key":"10.1016\/j.numecd.2023.07.025_bib22","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1111\/dom.13444","article-title":"Low incidence of gastrointestinal adverse events over time with a fixed-ratio combination of insulin glargine and lixisenatide versus lixisenatide alone","volume":"20","author":"Trujillo","year":"2018","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.numecd.2023.07.025_bib23","series-title":"SID-AMD Standard italiani per la cura del diabete mellito","year":"2018"},{"key":"10.1016\/j.numecd.2023.07.025_bib24","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s13300-020-00982-z","article-title":"Comparative effectiveness of switching from first-generation basal insulin to glargine 300 U\/ml or degludec 100 U\/ml in type 1 diabetes: the RESTORE-1 study","volume":"12","author":"Laviola","year":"2021","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.numecd.2023.07.025_bib25","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1007\/s00592-022-01925-9","article-title":"Comparative effectiveness and safety of glargine 300 U\/mL versus degludec 100 U\/mL in insulin-na\u00efve patients with type 2 diabetes. A multicenter retrospective real-world study (RESTORE-2 NAIVE STUDY)","volume":"59","author":"Fadini","year":"2022","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.numecd.2023.07.025_bib26","first-page":"2255","article-title":"Comparative effectiveness of Glargine 300 U\/mL vs. Degludec 100 U\/mL in patients with type 2 diabetes switching from 1\u00b0 generation basal insulins","volume":"32","author":"Buzzetti","year":"2022","journal-title":"Nutr Metabol Cardiovasc Dis"},{"key":"10.1016\/j.numecd.2023.07.025_bib27","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00125-019-05039-w","article-title":"2019 update to: management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"63","author":"Buse","year":"2020","journal-title":"Diabetologia"},{"key":"10.1016\/j.numecd.2023.07.025_bib28","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/dom.12626","article-title":"Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin","volume":"18","author":"Khunti","year":"2016","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.numecd.2023.07.025_bib29","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1007\/s13300-020-00905-y","article-title":"Glycemic control following GLP-1 RA or basal insulin initiation in real-world practice: a retrospective, observational, longitudinal cohort study","volume":"11","author":"Peng","year":"2020","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.numecd.2023.07.025_bib30","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1111\/dom.13345","article-title":"Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: comparative effectiveness of insulin glargine 300 units\/mL and insulin degludec in the DELIVER D+ cohort study","volume":"20","author":"Sullivan","year":"2018","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.numecd.2023.07.025_bib31","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.2337\/dc18-0559","article-title":"More similarities than differences testing insulin glargine 300 units\/mL versus insulin Degludec 100 units\/mL in insulin-naive type 2 diabetes: the randomized head-to-head BRIGHT trial","volume":"41","author":"Rosenstock","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2023.07.025_bib32","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/dom.14043","article-title":"Differential glycaemic control with basal insulin glargine 300 U\/mL versus degludec 100 U\/mL according to kidney function in type 2 diabetes: a subanalysis from the BRIGHT trial","volume":"22","author":"Haluz\u00edk","year":"2020","journal-title":"Diabetes Obes Metabol"},{"issue":"11","key":"10.1016\/j.numecd.2023.07.025_bib33","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1111\/dom.13840","article-title":"Fixed versus flexible combination of GLP-1 receptor agonists with basal insulin in type 2 diabetes: a retrospective multicentre comparative effectiveness study","volume":"21","author":"Morieri","year":"2019","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.numecd.2023.07.025_bib34","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1111\/dom.14739","article-title":"Real-world outcomes of addition of insulin glargine 300 U\/mL (Gla-300) to glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy in people with type 2 diabetes: the DELIVER-G study","volume":"24","author":"Bailey","year":"2022","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.numecd.2023.07.025_bib35","doi-asserted-by":"crossref","DOI":"10.1111\/dom.14986","article-title":"Impact of baseline kidney function on the effects of SGLT2 inhibitors on kidney and heart failure outcomes: a systematic review and meta-analysis of randomized controlled trials","author":"Maddaloni","year":"2023","journal-title":"Diabetes Obes Metabol"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475323002946?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475323002946?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:27:34Z","timestamp":1760545654000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475323002946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0939475323002946"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2023.07.025","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment intensification following glucagon-like peptide-1 receptor agonist treatment in type 2 diabetes: The RESTORE-G real-world study","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2023.07.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V. on behalf of The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University.","name":"copyright","label":"Copyright"}]}}